This consistency helps firsttime patients plan for work or family schedules
Martin Holst Lange, executive vice president and chief scientific officer at Novo Nordisk, stated, Wegovy is now uniquely positioned as the first and only GLP-1 treatment approved for MASH. He noted that this approval complements the proven weight loss, cardiovascular benefits, and broader evidence linked to semaglutide
Claims are usually paid out in 2-4 weeks
Virginia Commonwealth University (Medical Degree) University of Connecticut (Emergency Medicine Residency) Takashi Nakamura, MD Michael Wasef, MD Board-Certified Internal Medicine Physician Internal Medicine specialist focused on root-cause, patient-centered care via telemedicine
Monitoring body composition with tools like bioimpedance can also help identify significant losses in muscle or bone mass, which may signal the need for intervention